Molecular TherapyBioengineeringPeer-reviewed journal article
T cell correction pipeline for Inborn Errors of Immunity
Katariina MamiaiD, Sólrún KolbeinsdóttiriD, Kornel LabuniD, Zhuokun LiiD, Anna Zofia KomisarczukiD, Salla KeskitaloiD, Ganna ReintiD, Frida Loe Haugen, Britt Olaug Lindestad, Siv Skundberg Jensen, Thea Johanne Gjerdingen, Antti TuhkalaiD, Carolina Wieczorek ErvikiD, Pavel KopciliD, Nail FatkhutdinoviD, Karen Helene Bronken MartinseniD, Hans Christian Erichsen, Monika SzymańskaiD, Eero Tölö, Virpi GlumoffiD, Janna SaarelaiD, Trond Melbye MichelseniD, Camilla Schalin‐JänttiiD, Johanna OlweusiD, Eira LeinoneniD, , Emma Maria HaapaniemiiD
Abstract
CRISPR/Cas9 gene editing technology is a promising tool for correcting pathogenic variants for autologous cell therapies for Inborn Errors of Immunity (IEI). The present IEI correction strategies mainly focus on the knock-in of therapeutic cDNAs, or knockout of the disease-causing gene when feasible. These strategies address many single-gene defects but may disrupt gene expression and require significant optimization for each newly discovered IEI-causing gene, highlighting the need for complementary platforms that can precisely correct diverse pathogenic variants. Here, we present a safe and efficient T cell single nucleotide variant (SNV) correction pipeline based on homology-directed repair (HDR), suitable for diverse monogenic mutations. By using founder mutations of Deficiency of ADA2 (DADA2), Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and Cartilage Hair Hypoplasia (CHH) as IEI models, we show that our pipeline can achieve up to 80% bi-allelic editing, with resultant functional correction of the disease phenotype in patient T cells. We do not find detectable pre-malignant off-target effects or karyotypic, transcriptomic or proteomic aberrations upon profiling patient T cells with GUIDE-seq, single cell RNA sequencing, PacBio based long-read whole genome sequencing, and high-throughput proteomics. This study demonstrates that HDR-based SNV editing is a safe and effective option for IEI T cell correction and that it could be developed to an autologous T cell therapy, as the presented protocol is scalable for a GMP-compatible workflow. This study is a step towards the development of gene correction platform that targets a broad number of monogenic mutations. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=140 SRC="FIGDIR/small/610811v1_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@1f1eb47org.highwire.dtl.DTLVardef@18dbcc2org.highwire.dtl.DTLVardef@63862dorg.highwire.dtl.DTLVardef@1fe1561_HPS_FORMAT_FIGEXP M_FIG GRAPHICAL ABSTRACT C_FIG
- organism: human
- assay: scRNA-seq
- assay: long-read sequencing
- assay: proteomics
- research focus: cell type annotation
- research focus: gene regulatory network inference
- approach: deep learning
- approach: experimental assay
- Citations
- 4
- FWCI
- 0.96
- Field percentile
- top 28%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Protocol for Non-viral HDR-based CRISPR/Cas9 platform for small custom editing in primary T cells
Katariina Mamia, Anniken Solveig Matheson Sollano, … Emma Maria Haapaniemi·Frontiers in Genome EditingPeer-reviewed·Sep 30, 2026
- Editing of ADA2 Point Mutation in Human Hematopoietic Stem Cells
Pavel Kopcil, Carolina Wieczorek Ervik, … Emma Maria Haapaniemi·bioRxiv·Aug 14, 2025
- Gene Correction for SCID-X1 in Long-Term Hematopoietic Stem Cells
M. Pavel-Dinu, V. Wiebking, … M. Porteus·bioRxiv·Aug 22, 2018
- Allele-specific correction of ATAD3A pathogenic variants via template-free CRISPR-Cas9 editing and gene conversion
Taejeong Bae, Yohan Park, … Wan Hee Yoon·bioRxiv·Oct 23, 2025
- Multiplex HDR for Disease and Correction Modeling of SCID by CRISPR Genome Editing in Human HSPCs
- Highly efficient and versatile plasmid-based gene editing in primary T cells
M. Kornete, R. Marone, L. T. Jeker·bioRxiv·Jan 13, 2018